AbbVie (ABBV) has agreed to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West Pharmaceutical Services (WST).
West Pharmaceutical is selling all manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (ABBV) for total consideration of $112.5M at close, subject to working capital and other adjustments.
The transaction is anticipated to close in mid-2026 and will significantly expand AbbVie’s drug delivery device manufacturing capabilities and capacity.
AbbVie plans to hire around 200 employees at the site and invest more than $175M to acquire, as well as modernize and fully integrate it into its global manufacturing network.
The acquisition marks progress against AbbVie (ABBV)’s previously announced commitment to invest more than $10B of capital in the U.S. over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity.
SmartDose 3.5mL On-Body Delivery System revenues are anticipated to be around 4% of revenues in fiscal year 2025, West Pharmaceutical Services said in a separate news release. The company expects to provide additional details when it gives 2026 guidance on its fourth quarter 2025 earnings call in February.
Source: Press Release